Advertisement

ImmunoGen Inc. has begun clinical testing of its drug candidate SAR566658 in treating ovarian, breast, cervical, lung and pancreatic cancers.

The Cambridge biotech has worked with Paris pharmaceutical giant Sanofi-aventis to co-develop SAR566658, which uses ImmunoGen’s Targeted Antibody Payload technology. The technology has prompted a $1 million milestone payment from Sanofi-aventis, which has started clinical evaluations, to ImmunoGen (Nasdaq: IMGN).

SOURCE

Advertisement
Advertisement